Similar articles

• Blood-transmitted prions and variant Creutzfeldt-Jakob disease.

  Grady GF, Vyas GN. Grady GF, et al. Biologicals. 2007 Apr;35(2):75-7. doi: 10.1016/j.biologicals.2007.01.005. Epub 2007 Feb 20. Biologicals. 2007. PMID: 17317213 No abstract available.
• Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy.

  Brown P. Brown P. Haemophilia. 2007 Dec;13 Suppl 5:33-40. doi: 10.1111/j.1365-2516.2007.01572.x. Haemophilia. 2007. PMID: 18078395 Review.
• Removal of TSE agents from blood products.

  Foster PR. Foster PR. Vox Sang. 2004 Jul;87 Suppl 2:7-10. doi: 10.1111/j.1741-6892.2004.00444.x. Vox Sang. 2004. PMID: 15209867 Review. No abstract available.
• [Theoretical risk of vCJD transmission via blood transfusion. Leukocyte and erythrocyte depletion of the transfusion blood is a practice in many countries].

  Andersen O. Andersen O. Lakartidningen. 2002 Mar 21;99(12):1310-4. Lakartidningen. 2002. PMID: 11998162 Review. Swedish. No abstract available.
• Creutzfeldt-Jakob disease and the risk from blood or blood products.

  Will RG, Kimberlin RH. Will RG, et al. Vox Sang. 1998;75(3):178-80. Vox Sang. 1998. PMID: 9852403 Review.